SCHEMBL4775239

SCHEMBL4775239

O=[N+]([O-])c1cccc(-c2cc3c(Cl)ncnc3[nH]2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.54
ADORA2A P29274 1/20 0.52
ADORA1 P30542 1/20 0.52
LMNA P02545 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
NPC1 O15118 1/20 0.49
POLB P06746 1/20 0.49
DHFR P00374 1/20 0.47
MAPT P10636 3/20 0.46
PIK3CD O00329 1/20 0.45
PIK3CA P42336 1/20 0.45
PIK3CB P42338 1/20 0.45
PIK3CG P48736 1/20 0.45
PRKDC P78527 1/20 0.45
CDC7 O00311 1/20 0.43
EGFR P00533 1/20 0.42
SRC P12931 1/20 0.42
IDO1 P14902 2/20 0.42
GUSB P08236 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4338065 0.86 CSF1R (0.52) CSF1RADORA2AADORA1LMNAMEN1
SCHEMBL4771041 0.81 EGFR (0.62) CSF1REGFRSRC
SCHEMBL1899495 0.78 EGFR (0.55) CSF1RADORA2AADORA1DHFREGFR
SCHEMBL9047230 0.77 ALDH1A1 (0.51) LMNANPC1MAPTPIK3CDPIK3CA
SCHEMBL4770800 0.76 EGFR (0.72) CSF1REGFR
SCHEMBL4770796 0.76 EGFR (0.72) CSF1REGFR
SCHEMBL7495582 0.74 CSF1R (0.59) CSF1R
SCHEMBL12065795 0.74 BRAF (0.53) CSF1RMEN1KMT2ANPC1DHFR
SCHEMBL5357782 0.72 GABRP (0.54) MEN1KMT2ANPC1MAPTRAB9A
SCHEMBL7498524 0.72 DHFR (0.46) CSF1RDHFREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0938486-B1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 2008-01-16 EP disclosed
US-6180636-B1 USED TO INHIBIT THE TYROSINE KINASE ACTIVITY OF THE RECEPTOR FOR THE EPIDERMAL GROWTH FACTOR AND C-ERBB2 KINASE AND CAN BE USED AS ANTITUMOR AGENTS NOVARTIS AG (CH) 2001-01-30 US disclosed
EP-0938486-A1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION Novartis AG (CH) 1999-09-01 EP disclosed
WO-1998007726-A1 SUBSTITUTED PYRROLOPYRIMIDINES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 1998-02-26 WO disclosed